Have a feature idea you'd love to see implemented?
Let us know!
LYEL Lyell Immunopharma Inc
Price (delayed)
$0.5745
Market cap
$160.41M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.79
Enterprise value
$111.27M
Highlights
Lyell Immunopharma's debt has decreased by 12% YoY and by 3.5% QoQ
The revenue has dropped by 100% year-on-year but it has increased by 17% since the previous quarter
The gross profit has plunged by 100% YoY but it has grown by 17% from the previous quarter
Lyell Immunopharma's equity has decreased by 24% YoY and by 6% from the previous quarter
LYEL's quick ratio is down by 20% year-on-year and by 17% since the previous quarter
Key stats
What are the main financial stats of LYEL
Market
Valuations
Earnings
Shares outstanding
279.22M
Market cap
$160.41M
Enterprise value
$111.27M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.28
Price to sales (P/S)
2,337.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,766.13
Revenue
$63,000
Gross profit
$63,000
Net income
-$203.99M
EBIT
-$203.99M
EBITDA
-$184.33M
Free cash flow
-$156.23M
Per share
Balance sheet
Liquidity
EPS
-$0.79
EPS diluted
-$0.79
Free cash flow per share
-$0.61
Book value per share
$2.07
Revenue per share
$0
TBVPS
$2.42
Total assets
$619.22M
Total liabilities
$88.52M
Debt
$51.44M
Equity
$530.7M
Working capital
$416.53M
Debt to equity
0.1
Current ratio
13.43
Quick ratio
13.15
Net debt/EBITDA
0.27
Margins
Efficiency
Dividend
EBITDA margin
-292,582.5%
Gross margin
100%
Net margin
-323,792.1%
Operating margin
-344,628.6%
Return on assets
-30%
Return on equity
-34.6%
Return on invested capital
-35.5%
Return on capital employed
-34.8%
Return on sales
-323,792.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LYEL stock price
How has the Lyell Immunopharma stock price performed over time
Intraday
-3.23%
1 week
-13.41%
1 month
-14.74%
1 year
-74.12%
YTD
-10.23%
QTD
-10.23%
Financial performance
How have Lyell Immunopharma's revenue and profit performed over time
Revenue
$63,000
Gross profit
$63,000
Operating income
-$217.12M
Net income
-$203.99M
Gross margin
100%
Net margin
-323,792.1%
The revenue has dropped by 100% year-on-year but it has increased by 17% since the previous quarter
The gross profit has plunged by 100% YoY but it has grown by 17% from the previous quarter
The operating margin is up by 18% since the previous quarter
Lyell Immunopharma's net margin has increased by 17% QoQ
Growth
What is Lyell Immunopharma's growth rate over time
Valuation
What is Lyell Immunopharma stock price valuation
P/E
N/A
P/B
0.28
P/S
2,337.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,766.13
The EPS has declined by 3.9% year-on-year but it rose by 3.7% since the previous quarter
The stock's P/B is 65% less than its last 4 quarters average of 0.8
Lyell Immunopharma's equity has decreased by 24% YoY and by 6% from the previous quarter
The revenue has dropped by 100% year-on-year but it has increased by 17% since the previous quarter
LYEL's price to sales (P/S) is 62% less than its last 4 quarters average of 6138.9
Efficiency
How efficient is Lyell Immunopharma business performance
The ROE has contracted by 39% YoY and by 3.9% from the previous quarter
The ROA is down by 36% year-on-year and by 3.1% since the previous quarter
Lyell Immunopharma's ROIC has decreased by 31% YoY but it has increased by 3.3% from the previous quarter
The return on sales rose by 17% since the previous quarter
Dividends
What is LYEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LYEL.
Financial health
How did Lyell Immunopharma financials performed over time
The total assets has declined by 22% year-on-year and by 5% since the previous quarter
LYEL's quick ratio is down by 20% year-on-year and by 17% since the previous quarter
Lyell Immunopharma's debt is 90% lower than its equity
The debt to equity is up by 25% year-on-year and by 11% since the previous quarter
Lyell Immunopharma's equity has decreased by 24% YoY and by 6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.